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The term addiction, derived from a Latin word meaning ‘‘bound to’’ or ‘‘enslaved by,’’ was 
initially not linked to substance use. However, over the past several hundred years, 
addiction became associated with excessive alcohol and then drug use, such that by the late 
1980s it was largely synonymous with compulsive drug use (O’Brien et al., 2006). The core 
features of addiction are manifest in the continued performance of the behavior despite 
adverse consequences, compulsive engagement or diminished control over the behavior, 
and an appetitive urge or craving state prior to the behavioral engagement representing core 
elements (Holden, 2010). 
Addiction is a state of compulsive drug use; despite treatment and other attempts to control 
drug taking, addiction tends to persist. Hyman (2005) has summarized several studies 
where the authors have suggested that if the neurobiology is ultimately to contribute to the 
development of successful treatments for drug addiction, researchers must elucidate the 
molecular mechanisms by which drug-seeking behaviors are consolidated into compulsive 
use. Evidence at different levels of analysis suggest that addiction represents a pathological 
state of the neural mechanisms of learning and memory that, under normal circumstances, 
serve to shape survival behaviors related to the pursuit of rewards and the cues that predict 
them (Shultz et el., 1997; Montague et al., 2004; see Badiani et al., 2011 for review). The major 
substrates of persistent compulsive drug use are hypothesized to be molecular and cellular 
mechanisms that underlie long-term associative memories in several forebrain circuits 
(involving the ventral and dorsal striatum and prefrontal cortex) which receive inputs from 
midbrain dopamine neurons (see Hyman et al., 2006, for review). Also, the basolateral 
amygdala and nucleus accumbens core are key structures within limbic cortical-striatal 
circuitry where reconsolidation of a cue-drug memory occurs (Théberge et al., 2010). 
Vulnerability to stimulant addiction may depend on an impulsivity endophenotype. 
Impulsivity is the tendency to act prematurely without foresight, and is commonly 
associated with addiction to drugs, though its causal role in human addiction is unclear. 
Different groups (Dalley et al., 2007; Bezze et al., 2007 and Dalley et al., 2011) have 
characterized, in neurobehavioral and neurochemical terms, a rodent model of impulsivity 
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based on premature responses in an attentional task. Evidence suggests that high 
impulsivity on this task precedes the subsequent escalation of cocaine self-administration 
behavior (Dalley et al., 2007, and also a tendency towards compulsive cocaine-seeking (Belin 
et al., 2008) and to relapse (Economidou et al., 2009). On the other hand, excessive 
consumption of palatable food can trigger neuroadaptive responses in brain reward 
circuitries similar to those produced by drugs of abuse. Thus, congruent genetic 
vulnerabilities in brain reward systems can increase predisposition to drug addiction and 
obesity. Kenny (2011) has recently advanced our understanding of the brain circuitries that 
regulate hedonic aspects of feeding behavior, with evidence suggesting that obesity and 
drug addiction may share common mechanisms.  
Individuals take addictive drugs to elevate mood, but after repeated use these drugs 
produce serious unwanted effects, which include: tolerance to some drug effects, 
sensitization to others, and an adapted state–dependence, these setting the stage for 
withdrawal symptoms when drug use stops. The most serious consequence of repetitive 
drug taking is however addiction: a persistent state in which compulsive drug use escapes 
control, even when serious negative consequences ensue. Addiction is characterized by a 
long-lasting risk of relapse, which is often initiated by exposure to drug-related cues. 
Substantial progress has been made in understanding the molecular and cellular 
mechanisms of tolerance, dependence and withdrawal but, as yet, we understand little of 
the neural substrates of compulsive drug use and its remarkable persistence. Evidence exists 
for the possibility that compulsion and its persistence are based on a pathological 
usurpation of molecular mechanisms that are normally involved in memory (see Hyman 
and Malenka 2001 for review). 
Genetic studies to date have been most successful at identifying factors that influence the 
transition from regular use to dependence. Numerous and large twin studies have indicated 
a significant genetic contribution to the process of conversion from eventual use to 
established use before development of dependence. The availability of large cohort samples 
for nicotine and alcohol dependence has resulted in significant progress being made in 
understanding at least some of the genetic contributions to these addictions (Tsuang et al., 
1998, Kendler et al., 2003). Fewer studies have replicated specific genetic contributions to 
illicit drug use. Substance dependence can be thought of as a pharmacogenetic illness and, 
most likely, hundreds and more probably thousands of genetic variants will be required to 
fully explain the genetic input to this disease (see Bierut, 211 for review). 
1.1 Neurobiology of addiction 
Addictive drugs have in common the property that they are voluntarily self-administered 
by laboratory animals (usually avidly) (Di Chiara et al., 2004), and that they enhance the 
functioning of the reward circuitry of the brain (producing the 'high' that the drug user 
seeks). The core reward circuitry consists of an 'in-series' circuit linking the ventral 
tegmental area (VTA), nucleus accumbens (NAc) and ventral pallidum via the medial 
forebrain bundle. All addictive drugs have in common that they enhance (directly or 
indirectly or even transsynaptically) dopaminergic synaptic function in the NAc (Di Chiara 
et al., 2004), which is implicated in the reward process. Drug self-administration is regulated 
by NAc dopamine (DA) levels, which are retained within a specific elevated range (to 
maintain a desired hedonic level). The three classical sets of craving and relapse triggers are 
(a) reexposure to addictive drugs, (b) stress, and (c) reexposure to environmental cues 
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(people, places, things) previously associated with drug-taking behavior. Knowledge of the 
neuroanatomy, neurophysiology, neurochemistry and neuropharmacology of addictive 
drug action in the brain is currently producing a variety of strategies for 
pharmacotherapeutic treatment of drug addiction, some of which appear promising 
(Gardner, 2011). Addictive drugs target the mesocorticolimbic dopamine (DA) system. This 
system originates in the VTA and projects mainly to the NAc and prefrontal cortex (PFC), 
affecting glutamatergic and GABAergic synaptic transmission in all three brain areas. These 
changes are refered to as drug-evoked synaptic plasticity, which outlasts the presence of the 
drug in the brain and contributes to the reorganization of neural circuits. While in most 
cases these early changes are not sufficient to induce the disease, with repetitive drug 
exposure, they may add up and contribute to addictive behavior (see Lüscher and Malenka, 
2011 for review). 
1.2 Learning and memory in addictive behavior 
Two forms of cellular and synaptic plasticity, long-term potentiation (LTP) and long-term 
depression (LTD) remain the most extensively studied. They are considered the cellular and 
molecular basis of learning and memory (Kandel, 2004; Negrete-Díaz et al., 2007; Adermark 
et al., 2009; Abusch and Akirav, 2010; Collingridge et al., 2010; Huang et al., 2011, Figure 1).  
 
Fig. 1. LTP and LTD. Induction protocols and cellular mechanisms. Ai transverse hippocampal 
slice and estándar positioning of stimulating and recording electrodes. Hippocampus is the 
structure in which plasticity mechanisms have been more extensively estudied. Aii, 
representation of presynaptic and postsynaptic neurons at synapse between CA3 and CA1 
pyramidal cells. Bi, LTP protocol,  tetanic (100 Hz, 1s) stimulation of presynaptic neurons 
induce and increase of the amplitude of excitatory postsynaptic potencial EPSP (Bii) recorded 
from postsynaptic neurons. Ci, LTD protocol, stimulation at 1 Hz during 15 minutes induce a 
decrease of the amplitude of the EPSP (Cii) recorded from postsynaptic neurons. D, schematic 
description of intracellular mechanisms involved in LTP and LTD 
 
Addictions – From Pathophysiology to Treatment 
 
70
In addition, they can be used to demonstrate the repertoire of enduring modifications of 
individual synapses, circuits or neural networks. A classic triad arrangement of DA terminal 
varicosities, dendritic spines, and cortical inputs allows dopamine to enhance spike-time-
dependent plasticity (STDP) at active cortico-striatal and cortico-cortical synapses. The 
induced LTP and LTD are candidate mechanisms for phasic DA signal to mediate 
behavioral learning. Thus, by affecting striatal and cortical plasticity, addictive drugs could 
lead to long-lasting changes of the motor, reward, and cognitive functions of these 
structures, striatum and PFC (Schultz, 2011). Conditioned stimuli (CSs) by Pavlovian 
association with reinforcing drugs (unconditioned stimuli; US) are thought to play an 
important role in the acquisition, maintenance and relapse of drug dependence. Bassareo et 
al. (2007) using microdialysis investigated the impact of pavlovian drug CSs on behaviour 
and on basal and drug-stimulated transmitter levels in three terminal DA areas: NAc shell 
and core, and the PFC. Drug CSs elicited incentive reactions and released DA; pre-exposure 
to CSs potentiated DA release to drug (Schultz, 2011). Théberge et al. (2010) demonstrated 
that the basolateral amygdala (BLA) and the NAc core are two structures importantly 
involved in the reconsolidation of a cocaine–CS memory. They show that, depending on the 
psychological processes involved, different neural substrates within limbic cortical-ventral 
striatal circuitry are required for the reconsolidation of a Pavlovian memory. Milton and 
Everitt, 2010, have shown with more detail the memory reconsolidation mechanisms 
underlying conditioned reinforcement and its relationship to drug addiction and the 
subsequent translation to the clinic of preclinical works.  
1.3 Dopamine in addiction  
DA's contribution appears to chiefly cause 'wanting' for hedonic rewards, more than 'liking' 
of or learning of those rewards (Schultz, 2011). However, the debate continues over the 
precise causal contribution made by mesolimbic DA systems to reward. Recent evidence 
indicates that DA is neither necessary nor sufficient to mediate changes in hedonic 'liking' 
for sensory pleasures. Other recent evidence indicates that DA is not needed for new 
learning, and not sufficient to directly mediate learning by causing teaching or prediction 
signals. Drugs of abuse promote DA signals, short circuit and sensitize dynamic mesolimbic 
mechanisms that evolved to attribute incentive salience to rewards (Berridge, 2007). The 
potential use of drugs to enhance cognition, emotion, and executive function has 
engendered controversy despite the fact that few such agents exist today. Hyman (2011) 
provided a context for discussions based on medical, regulatory, and ethical concerns that 
have been raised by the possibility that enhancers will emerge from current efforts to 
discover drugs for neuropsychiatric disorders. Addiction coopts the brain's neuronal circuits 
necessary for insight, reward, motivation, and social behaviors. This functional overlap 
results in addicted individuals making poor choices despite awareness of the negative 
consequences (Volkow et al., 2011). This explains why previously rewarding life situations 
and the threat of judicial punishment cannot stop drug taking and why a medical rather 
than a retributional approach is more effective in curtailing addiction.  
We describe in this chapter the effects of cannabinoids, cocaine and amphetamines on the 
nervous system with particular emphasis on the effects of these compounds in plasticity 
processes. As the DA transporter is central to the effects of these drugs, we dedicate some 
special attention to the physiology of this type of transporter.  
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2. Cannabinoids (Table 1) 
The use of marijuana for recreational and medicinal purposes has resulted in a large 
prevalence of chronic marijuana users (WHO, 2012). In the present decade, cannabis abuse 
has grown more rapidly than cocaine and opiate abuse. About 147 million people, 2.5% of 
the world population, consume cannabis (annual prevalence) compared with 0.2% 
consuming cocaine and 0.6% consuming amphetamine (WHO, 2012). The most rapid 
growth in cannabis abuse since the 1960s has been in developed countries in North America, 
Western Europe and Australia (WHO, 2012). Consequences of chronic cannabinoid 
administration include profound behavioral tolerance and withdrawal symptoms upon 
drug cessation. A marijuana withdrawal syndrome is only recently gaining acceptance as 
being clinically significant. Similarly, laboratory animals exhibit both tolerance and 
dependence following chronic administration of cannabinoids. These animal models are 
being used to evaluate the high degree of plasticity that occurs at the molecular level in 
various brain regions following chronic cannabinoid exposure (Lichtman and Martin, 2005).  
2.1 The endocannabinoid (eCB) signaling system 
The isolation and identification, in 1964 (Gaoni and Mechoulam, 1964), of delta-9-
tetrahydrocannabinol (Δ9-THC), the primary psychoactive compound in cannabis, opened 
the door to a whole new field of medical research. The exploration of the therapeutic 
potential of THC and other natural and synthetic cannabinoid compounds was paralleled by 
the discovery of the endocannabinoid system, comprising cannabinoid receptors and their 
endogenous ligands, which offered exciting new insights into brain function (see Isbell et al., 
1967 for review). Besides its well-known involvement in specific brain functions, such as 
control of movement (Di Marzo et al., 2000; Keeney et al., 2008; Fuss and Gass, 2010), 
memory (Deadwyler et al., 2007; Deadwyler and Hampson, 2008) and emotions (Paule et al., 
2005; Tan et al., 2010), the endocannabinoid system plays an important role in fundamental 
developmental processes such as cell proliferation, migration and differentiation (Trezza et 
al., 2008, 2012). For this reason, changes in its activity during stages of high neuronal 
plasticity, such as the perinatal and the adolescent period, can have long-lasting 
neurobehavioral consequences (see Trezza et al., 2008 for review). Two subtypes of 
cannabinoid receptors (CBRs) have been identified to date, the CB1 receptor, essentially 
located in the CNS, but also in peripheral tissues, and the CB2 receptor, found only at the 
periphery. Many of the effects of cannabinoids, such as delta (9)-THC (Δ9-THC), the 
psychoactive principle of cannabis sativa, and endocannabinoids (eCBs) are mediated by 
these two metabotropic receptors, although additional receptors may be implicated. Both 
CB1 and CB2 are G-protein-coupled receptors (GPCRs), primarily operating through 
inhibitory G proteins, and are subject to the same pharmacological influences of other 
GPCRs (Chaperon and Thiébot, 1999; Basavarajappa et al., 2009). Freund et al. (2003) 
described a fine-grain anatomical distribution of the neuronal cannabinoid receptor CB1 in 
brain areas, emphasizing its general presynaptic localization and role in controlling 
neurotransmitter release, synaptic plasticity and network activity patterns. The eCBs as 
ligands for these CB1 and CB2 receptors are a family of lipidic mediators that signal through 
the same cell surface receptors that are targeted by Δ9-THC. Unlike neurotransmitter 
molecules that are typically held in vesicles before synaptic release, eCBs are liberated 
directly after synthesis and, once released, travel in a retrograde direction to suppress 
presynaptic neurotransmitter release through activation of CBRs (Basavarajappa, 2007). 
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Presence of an 'amotivational' 
syndrome 
Limbic system Paule, 2005 
Regulation of ion channels, 







Profound behavioral tolerance 
and withdrawal symptoms 
Limbic system 
 
Lichtman & Martin, 
2005 




Lupica et al., 2004 
 
↑ Risk of developing psychotic 
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↑ Density of cannabinoid CB1R 
binding   
Corticolimbic regions Fernandez-Espejo et 
al., 2009 
↓ Hippocampal encoding and 
the ability to encode information 
into short-term memory 
Hippocampus 
 
Deadwyler et al., 
2007; Deadwyler and 
Hampson, 2008. 




Abush & Akirav, 2010 
 





in the striatum 




Decrease in LTP prevented by 
pharmacological inhibition or 
deletion of the CB1R  
Hippocampus Fan et al., 2010 
Metaplastic effects on brain 
cortex 
Motor cortex Koch et al., 2009 
↑Response of mPFC neurons 
Modulate emotional memory 
formation 
mPFC, BLA Laviolette & Grace, 
2006 
↓ Gray matter Cerebral cortex Stone et al., 2011 
Blocked LTP and acquisition of 
conditioned fear memories by 
CB1R antagonist 
BLA-PLC pathway Tan et al., 2010 
Changes in cell proliferation, 




Trezza et al., 2008 
Table 1. Plastic changes on brain regions by chronic use of marijuana, Δ9-THC 
administration or CB1R pharmacological manipulation. 
(Abbreviations: BLA: basolateral amygdale; CB1R: type 1 cannabinoid receptor; eCB: endocannabinoid; 
GABA: gamma aminobutyric acid; LTP: long-term potentiation; LTD: long-term depression; mPFC: 
medial prefrontal cortex; PLC: prelimbic cortex; PFC: prefrontal cortex). 
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Recent results have suggested that the eCB system may play an important role in early 
neuronal development having been detected from the earliest stages of embryogenesis and 
throughout pre- and postnatal development. Additionally, the eCB signaling system is 
being found to be involved in an increasing number of neuropathological conditions, with 
widespread roles being invoked in neurodegenerative disorders. The fact that eCB signaling 
is mostly inhibitory, imparts eCBs with the ability to modulate synaptic efficacy with a wide 
range of functional consequences and provides unique therapeutic possibilities in central 
nervous system (CNS) diseases, including alcoholism, Alzheimer's disease, Parkinson's 
disease, Huntington's disease, and multiple sclerosis (see Basavarajappa, 2007; 
Basavarajappa et al., 2009 for reviews).  
Although CB1 receptors are distributed throughout the brain, they are found at very high 
levels in the cerebellum. Edwards and Skosnik (2007) have integrated two separate literatures. 
The first literature demonstrates that the eCB system mediates synaptic plasticity, specifically 
LTD of parallel fibers at the parallel fiber-Purkinje junction in the cerebellar cortex. The second 
literature suggests that LTD at this junction is necessary for the acquisition of the primary 
dependent variable in delay eyeblink conditioning. Also, they discuss recent evidence from 
CB1 knockout mice, human cannabis users, and schizophrenia patients, with the expectation 
that translational research on the cannabinoid system will be advanced. Wiskerke et al. (2008) 
summarize studies in which have been used CB1R knockout mice as well as CB1 antagonists 
to elucidate the role of this neurotransmitter system in psychostimulant addiction. CB1 
receptors appear not to be involved in psychostimulant reward, nor in the development of 
dependence to such substances. In contrast, the eCB system appears to play a role in the 
persistence of psychostimulant addiction (see Wiskerke et al., 2008 for review). Interactions of 
the eCB system with afferent glutamatergic and possibly dopaminergic projections to the 
nucleus accumbens are most likely involved and CB1 receptors seem to modulate drug-related 
memories, in line with the hypothesized role of the eCB system in memory-related plasticity. 
Together, these findings suggest that modulators of the eCB system represent a promising 
novel type of therapy to treat drug addiction.  
2.2 The reward system 
The reward circuitry of the brain consists of neurons that synaptically connect a wide 
variety of nuclei. Of these brain regions, the VTA and the NAc play key roles in the 
processing of rewarding environmental stimuli and in drug addiction. The psychoactive 
properties of marijuana are produced by Δ9-THC, interacting primarily with CB1 receptors 
in a large number of brain areas. However, it is the activation of CB1 receptors located in 
reward circuits that is thought to be instrumental in sustaining the self-administration of 
marijuana in humans, and in mediating the anxiolytic and pleasurable effects of the drug. It 
has been suggested that, whereas Δ9-THC alters the activity of central reward pathways in a 
manner that is consistent with other abused drugs, the cellular mechanism through which 
this occurs is likely different, relying upon the combined regulation of several afferent 
pathways to the VTA (see Lupica et al., 2004 for review). 
2.3 Cannabis, cannabinoids and neuronal plasticity 
Changes in synaptic efficacy are thought to be crucial to experience-dependent 
modifications of neural function. eCB-mediated plasticity encompasses many forms of 
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transient and long-lasting synaptic depression and is found at both excitatory and inhibitory 
synapses. Thus, the eCB system is emerging as a major player in synaptic plasticity and, 
given the wide distribution of CB1 receptors in the CNS, the list of brain structures and 
synapses expressing eCB-mediated plasticity is likely to expand (see Chevaleyre et al., 2006 
for review). Glutamate is the principal excitatory neurotransmitter in CNS and altered 
glutamatergic transmission during critical periods (such as first postnatal weeks) may 
disturb circuitry in specific brain areas (including cortex and hippocampus), particularly in 
experience-dependent maturation. Recent hypotheses regarding disturbances in 
strengthening and pruning of synaptic connections in the PFC, and the link with latent 
psychotic disorders suggest that cannabis-induced schizophrenia is due to a distortion of 
normal late postnatal brain maturation (see Bossong and Niesink, 2010 for review). In this 
respect, cannabis use during adolescence increases the risk of developing psychotic 
disorders later in life. In animals, Bossong and Niesink (2010) postulated that adolescent 
exposure to Δ9-THC transiently disturbs physiological control of the eCB system over 
glutamate and GABA release. As a result, Δ9-THC may adversely affect adolescent 
experience-dependent maturation of neural circuitries within prefrontal cortical areas. 
Depending on dose, exact time window and duration of exposure, this may ultimately lead 
to the development of psychoses like schizophrenia. 
There is substantial evidence that cannabis abuse is a risk factor for psychosis in genetically 
predisposed people, may lead to a worse outcome of the disease, or it can affect normal 
brain development during adolescence, increasing the risk for schizophrenia in adulthood. 
On the other hand, the eCB system is altered in schizophrenia (increased density of CB1 
receptors binding in corticolimbic regions). Dysregulation of this system can interact with 
neurotransmitter systems in such a way that a "cannabinoid hypothesis" can be integrated in 
the neurobiological hypotheses of schizophrenia. Also, there is evidence that some genetic 
alterations of the CNR1 gene can act as a protectant factor against schizophrenia or can 
induce a better pharmacological response to atypical antipsychotics (see Fernandez-Espejo 
et al., 2009 for review). Awareness of cannabis dependence as a clinically relevant issue has 
grown in recent years. Clinical and laboratory studies demonstrate that chronic marijuana 
smokers can experience withdrawal symptoms upon cessation of marijuana smoking and 
have difficulty abstaining from marijuana use. The behavioral effects that directly contribute 
to the maintenance of chronic marijuana smoking are reward, subjective effects, and the 
positive and negative reinforcing effects of marijuana, Δ9-THC or synthetic cannabinoids 
(Cooper and Haney, 2008). 
Studies using population codes derived from ensembles of hippocampal neurons have been 
assessed to determine whether eCBs were active when rats performed a short-term memory 
task in presence or absence of CB1 receptor antagonists or agonists. Results show that eCBs, 
like marijuana, reduced hippocampal encoding necessary to perform long-delay trials 
(Deadwyler et al., 2007). Also, CB1 receptor antagonism blocked an inherent hippocampal 
memory encoding bias used by all animals. These findings suggest a direct relationship 
between the actions of cannabinoids on hippocampal processes and the ability to encode 
information into short-term memory Deadwyler and Hampson, 2008. Considerable 
evidence demonstrates that cannabinoid receptor agonists impair, whereas cannabinoid 
receptor antagonists improve, memory and plasticity (Ademark et al., 2009; Fan et al., 2010). 
However, recent studies suggest that the effects of cannabinoids on learning do not 
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necessarily follow these simple patterns, particularly when emotional memory processes are 
involved. Abush and Akirav (2010) have investigated the involvement of the CB system in 
hippocampal learning and plasticity using behavioral task and cellular models of learning 
and memory (LTP and LTD). They found that i.p. agonist administration impaired LTP in 
the Schaffer collateral-CA1 projection, whereas an inhibitor of eCB reuptake facilitated LTD. 
These findings suggest that the diverse effects of the cannabinoid system on CA1 memory 
and plasticity cannot be categorized simply into an impairing or an enhancing effect of 
cannabinoid activation and deactivation, respectively. Previous studies have indicated that 
eCB mobilization at excitatory synapses might be regulated by afferent activation. LTD at 
striatal synapses is mediated by postsynaptic eCB release and presynaptic CB1 receptor 
activation. Adermark et al. (2009) have examined changes in synaptic strength induced by 
activation of L-type calcium channels at glutamatergic and gamma-aminobutyric acid 
(GABA)ergic synapses in the striatum. They found that the basic mechanisms for eCB 
signaling are the same at glutamatergic and GABAergic synapses. LTD was blocked in slices 
treated with AM251, a CB1 receptor antagonist, but established depression was not reversed 
at either glutamatergic and GABAergic synapses. It is suggested that the level of neuronal 
firing regulates eCB signaling by modulating release from the postsynaptic cell, as well as 
interacting with presynaptic mechanisms to induce LTD at both glutamatergic and 
GABAergic synapses in the striatum. 
Chronic use of marijuana impairs synaptic plasticity and cognitive function. Fan et al. (2010) 
found that repeated in vivo exposures to Δ9-THC for 7 consecutive days significantly 
impaired hippocampal LTP of excitatory glutamatergic synaptic transmission, and this 
decrease in LTP was prevented by pharmacological inhibition or deletion of the CB1 
receptor. They showed that reduced expression and function of the GluR subunits and 
phosphorylation of cAMP response element-binding (CREB) may underlie the impaired 
long-term synaptic plasticity induced by repeated in vivo exposure to Δ9-THC. In animal 
models, the CB system has been convincingly implicated in the regulation of long-lasting 
synaptic plasticity. Both LTP and LTD can be induced in the human motor cortex by 
transcranial magnetic theta burst stimulation (TBS). Koch et al. (2009) explored the potential 
involvement of the CB system in TBS-induced synaptic plasticity in humans with multiple 
sclerosis. Continuous TBS induced the expected inhibition of motor-evoked potentials 
(MEPs) before cannabis-based preparation exposure (Sativex), whereas it caused a persisting 
enhancement of MEP amplitude 4 weeks after. The LTP-like phenomenon induced by 
intermittent TBS was conversely unaffected by preparation exposure. These results indicate 
that cannabis ingredients have metaplastic effects on the motor cortex. Laviolette and Grace 
(2006), using in vivo single-unit recordings in rats, found that a CB1 receptor agonist 
potentiated the response of medial prefrontal cortical (mPFC) neurons to olfactory cues 
paired previously with a footshock, whereas this associative responding was prevented by a 
CB1 receptor antagonist, providing the first demonstration that CB signaling in the mPFC 
can modulate the magnitude of neuronal emotional learning plasticity and memory 
formation through functional inputs from the basolateral amygdala (BLA, Laviolette and 
Grace, 2006). 
Individuals with an “at risk mental state” (ARMS) are greatly more susceptible to 
developing a psychotic illness. There has been considerable interest in the interaction 
between psychosis risk and substance use. Cannabis at low to moderate intake may be 
associated with lower gray matter in both ARMS subjects and healthy volunteers, possibly 
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representing low-level cortical damage or change in neural plasticity (Stone et al., 2011). The 
CB1 receptor system is functionally involved in the processing and encoding of emotionally 
salient sensory information, learning and memory. The CB1 receptor is found in high 
concentrations in brain structures that are critical for emotional processing, including the 
BLA and the mPFC. Synaptic plasticity in the form of LTP within the BLA-mPFC pathway is 
an established correlate of exposure to emotionally salient events (Laviolette and Grace, 
2006). In vivo LTP studies showed that systemic pretreatment with AM-251, dose-
dependently block LTP along the BLA-PLC pathway, and also the behavioral acquisition of 
conditioned fear memories (Tan et al., 2010). Experiments show that when CB1 receptor 
transmission within the BLA-PFC circuit was pharmacologically blocked, this prevented the 
acquisition of emotionally salient associative memory. These results indicate that 
coordinated CB1 receptor transmission within the BLA-PFC pathway is critically involved 
in the encoding of emotional fear memories and modulates neural plasticity related to the 
encoding of emotionally salient associative learning (Tan et al., 2010). 
3. Cocaine (Table 2) 
Behavioral sensitization is the augmented motor-stimulant response that occurs with 
repeated, intermittent exposure to most drugs of abuse, including cocaine. Sensitization, 
which is a long-lasting phenomenon, is thought to underlie drug craving and relapse to 
drug use (Steketee et al., 2003). The neural mechanisms of sensitization have focused on the 
NAc and VTA that comprise a part of the mesolimbic DA system. Cocaine sensitization 




Effect on brain plasticity and 
behaviour 
Structures Autor 
Cocaine Induced behavioural sensitization mPFC, NAc, VTA Steketee, 2003; 2005 
Induced conditioned place 
preference  
mPFC, NAc shell, 
VTA 
McBride et al., 1999 
↑ BDNF, ↓ mGluR5, LTD impared NAc shell Huang et al., 2011 
↑ DA transmission and induce CTA NAc shell Di Chiara et al., 2004 
Behavioral deficits at birth and/or 
during adulthood  
Limbic system Lidow, 2003 
 









Aston-Jones et al., 
2009 
Shift from impulsivity to 
compulsivity during the 
development of addictive behavior 
PFC,  ventral and 
dorsal striatum 
Belin et al., 2008 
Increased MeCP2 expression and 
microRNA  
Dorsal striatum Welberg, 2010 
Table 2. Plastic changes on brain regions by chronic use of cocaine.  
(Abbreviations: BDNF: brain-derived neurotrophic factor; CTA: conditioned taste avoidance; DA: 
dopamine; LTD: long-term depression; MeCP2: methyl CpG binding protein 2; mGluR5: type 5 
metabotropic glutamate receptor; mPFC: medial prefrontal cortex; NAc: nucleus accumbens; VTA: 
ventral tegmental area). 
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to the VTA and NAc. Repeated cocaine exposure alters DA, gamma-aminobutyric acid 
(GABA), and glutamate regulation of pyramidal cell activity (Di Chiara et al., 2004; Huang 
et al., 2011), with cocaine-induced alterations in cortical transmission occuring in two 
phases. During early withdrawal from repeated cocaine exposure, changes in 
neurotransmitter release are thought to underlie the decreased inhibitory modulation of 
pyramidal projection neurons. Following more prolonged withdrawal, the attenuation in 
inhibitory transmission appears to occur at the receptor level (Steketee, 2005). 
3.1 Cocaine and dopaminergic system 
Neuroadaptation in the NAc, a central component of the mesolimbic DA system, has been 
implicated in the development of cocaine-induced psychomotor sensitization and relapse to 
cocaine seeking (Zhang et al., 2001; Anderson et al., 2003; see Steketee, 2005 for review). 
Recent results suggest that withdrawal from repeated cocaine exposure may result in 
increased brain-derived neurotrophic factor (BDNF) levels in the NAc shell, which leads to a 
selective downregulation of mGluR5 and thereby impairs the induction of mGluR-
dependent LTD (Huang et al., 2011). The effects of BDNF on cocaine-seeking are brain 
region-specific. Infusion of BDNF into subcortical structures, like the NAc and VTA, 
enhances cocaine-induced behavioral sensitization and cocaine-seeking. Conversely, 
repeated administration of BDNF antiserum into the NAc during chronic cocaine self-
administration attenuates cocaine-induced reinstatement. Three weeks after BDNF 
antiserum infusion in animals with a cocaine self-administration history, suppressed basal 
levels of glutamate are normalized, and a cocaine prime-induced increase in extracellular 
glutamate levels in the NAc is prevented (McGinty et al., 2010). Although the development 
of behavioral sensitization to psychostimulants such as cocaine and amphetamine is 
confined mainly to one nucleus in the brain, the VTA, this process is nonetheless complex, 
involving an interplay between neurotransmitters, neuropeptides and trophic factors. 
Calcium-stimulated signalling molecules, including the calcium/calmodulin-dependent 
protein kinases, and the Ras/mitogen-activated protein kinases, represent the major 
biochemical pathways whereby converging extracellular signals are integrated and 
amplified, resulting in the biochemical and molecular changes in DA neurons in the VTA 
that represent the critical neuronal correlates of the development of behavioral sensitization 
to psychostimulants (see Licata and Pierce, 2003 for review).  
Using a mouse model of behavioral sensitization, Huang et al. (2011) showed that animals 
withdrawn from repeated cocaine exposure have a selective deficit in the ability to elicit 
metabotropic glutamate receptor (mGluR)-dependent LTD in the shell of the NAc in 
response to bath application of the group I mGluR agonist DHPG. Experiments 
demonstrated that the impaired DHPG-LTD is likely attributable to a loss of mGluR5 
function. Quantitative real-time reverse transcriptase-PCR and Western blot analysis 
revealed significant downregulation of mGluR5, but not mGluR1, mRNA or protein levels 
in the NAc shell. The inhibitory effect of repeated cocaine exposure on DHPG-LTD was 
selectively prevented when cocaine was coadministered with a selective D1 receptor 
antagonist. Furthermore, the levels of BDNF protein in the NAc shell increased 
progressively after cocaine withdrawal, and crucially, the impairment of DHPG-LTD in the 
NAc shell was not found in slices from BDNF-knock-out mice after cocaine withdrawal. 
Recent evidence suggests that CB1Rs may represent effective targets for therapeutic agents 
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used to treat cocaine relapse. Li et al. (2008) determinated whether CBRs play a similar role 
in relapse to ketamine abuse. To establish a ketamine reinstatement model in the 
conditioned place preference paradigm, rats were trained to develop place preference 
conditioned by ketamine, which was subsequently extinguished through daily exposure to 
the test chambers in the absence of ketamine. The effects of rimonabant, a CB1Rs antagonist, 
were investigated on reinstatement of ketamine-induced place preference. While ketamine 
priming injections reinstated extinguished place preference, rimonabant administration 
significantly attenuated the reinstatement of ketamine-induced place preference in a dose-
dependent manner. Importantly, rimonabant itself did not produce conditioned place 
preference or place aversion. Since the reinstatement effects of ketamine administration 
were inhibited by rimonabant, these findings suggest that a CB1 receptor antagonist may be 
useful in preventing relapse to ketamine abuse. VTA DA neurons play a pivotal role in 
processing reward-related information and are involved in drug addiction and mental 
illness in humans (Wise, 2004). Information is conveyed to the VTA in the large part by 
glutamatergic afferents that arise in various brain nuclei, including the pedunculopontine 
nucleus (PPN).  
In rat brain slice preparations, Good and Lupica (2010) found that PPN stimulation activates 
afferents targeting GluR2-containing AMPA receptors (AMPAR) on VTA DA neurons, and 
these afferents did not exhibit long-term depression (LTD). In contrast, activation of 
glutamate afferents onto the same DA neurons via stimulation within the VTA evoked both, 
excitatory postsynaptic currents EPSCs mediated by GluR2-lacking AMPARs which showed 
LTD, and EPSCs mediated by GluR2-containing AMPA receptors that did not express LTD. 
Single cocaine injections increase GluR2-lacking AMPA receptors at all glutamate synapses 
on VTA dopamine neurons (and this permitted LTD expression in both pathways), whereas 
Δ9-THC selectively increased GluR2-lacking AMPA receptors at subcortical PPN synapses 
(and permitted LTD in the PPN pathway only), suggesting that different drugs of abuse 
may exert influence over distinct sets of glutamatergic afferents to VTA DA neurons, which 
may thereby be associated with different reinforcing or addictive properties of these drugs. 
Microdialysis studies in animals have shown that addictive drugs preferentially increase 
extracellular DA levels in the NAc rather than in the core. However, by acting directly on 
the brain, drugs bypass the adaptive mechanisms (habituation) that constrain the 
responsiveness of accumbens shell DA to food reward, abnormally facilitating Pavlovian 
incentive learning and promoting the acquisition of abnormal DA-releasing properties by 
drug conditioned stimuli (See Di Chiara & Bassareo, 2007 for review). Thus, whereas 
Pavlovian food conditioned stimuli release core but not shell DA, drug conditioned stimuli 
do the opposite, releasing shell but not core DA. This process, which results in the 
acquisition of excessive incentive-motivational properties by drug conditioned stimuli has 
been suggested to contribute to the initiation of the drug addiction process (Imperato and Di 
Chiara, 1986; Di Chiara and Bassareo, 2007).  
Brain imaging studies, while extending these finding to humans, have shown a correlation 
between psychostimulant-induced increase of extracellular DA in the striatum and self-
reported measures of liking and euphoria (Volkow et al., 2002a; 2002b). Although a correlate of 
drug reward, independent from associative learning and performance is difficult to obtain in 
animals, conditioned taste avoidance (CTA) might meet these requirements. Addictive drugs 
induce CTA to saccharin most likely as a result of anticipatory contrast of saccharin over drug 
reward. Consistently with a role of DA in drug reward, D2 or combined D1/D2 receptor 
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blockade abolishes cocaine, amphetamine and nicotine CTA. Intracranial self-administration 
studies with mixtures of D1 and D2 receptor agonists point to the NAc shell as the critical site 
of DA reward (Di Chiara et al., 2004; Bassareo et al., 2007). NAc shell DA acting on D1 
receptors is also involved in Pavlovian learning through pre-trial and post-trial consolidation 
mechanisms and in the utilization of spatial short-term memory for goal-directed behaviour 
(Volkow et al., 2011). Stimulation of NAc shell DA transmission by addictive drugs is shared 
by a natural reward like food, but lacks its adaptive properties (habituation and inhibition by 
predictive stimuli). These peculiarities of drug-induced stimulation of DA transmission in the 
NAc shell result in striking differences in the impact of drug-conditioned stimuli on DA 
transmission. It is speculated that drug addiction results from the impact exerted on behavior 
by the abnormal DA stimulant properties acquired by drug-conditioned stimuli as a result of 
their association with addictive drugs (Di Chiara et al., 2004; Everitt & Robbins, 2005). Di 
Chiara and Bassareo (2007) have summarized that addictive drugs share with palatable food, 
the property of increasing extracellular DA, preferentially in the NAc shell rather than in the 
core. However, by acting directly on the brain, drugs bypass the adaptive mechanisms 
(habituation) that constrain the responsiveness of NAc shell DA to food reward, abnormally 
facilitating Pavlovian incentive learning and promoting the acquisition of abnormal DA-
releasing properties by drug conditioned stimuli. Thus, whereas Pavlovian foods conditioned 
stimuli release core but not NAc shell DA, drug conditioned stimuli do the opposite, releasing 
shell but not NAc core DA. Neuroadaptive processes related to the chronic influence of drugs 
on subcortical DA might secondarily impair the function of prefronto-striatal loops, resulting 
in impairments in impulse control and decision making that form the basis for the compulsive 
feature of drug seeking and its relapsing character (Belin and Everitt, 2010). 
3.2 Prenatal cocaine exposure 
The extent to which cocaine abuse by pregnant women can affect development of  
their offspring remains a matter of significant debate. In large part, this is due to difficulties 
in accurate determination of the type, dose, and pattern of cocaine administration by drug 
abusing women as well as to difficulties in controlling for a wide range of potentially 
confounding variables, such as other drugs used, race, socioeconomic status, and level of 
prenatal care. Examination of the effects of prenatal cocaine exposure in highly controlled 
nonhuman primate models represents an important complement to the human research. 
Data obtained in several different rhesus monkey models of cocaine exposure in utero, has 
demonstrated the potential of prenatal cocaine exposure to interfere with structural and 
biochemical development of the brain leading to behavioral deficits at birth and/or during 
adulthood. The differences in the outcomes between individual models also suggest that the 
specific types and severity of cocaine effects are likely dependent on the route, dose, 
gestational period, and daily pattern of administration (see Lidow, 2003 for review). 
Nonhuman primates (rhesus monkeys, Macaca mulatta) have been used to study the effects 
of chronic drug exposures on brain function during different stages of development. In the 
case of the marijuana studies, exposures occurred during the adolescent period; for the 
cocaine studies, exposures occurred in utero. A battery of behavioral tasks, designed to 
assess aspects of motivation, visual discrimination, time perception, short-term memory, 
and learning, was used to monitor treatment effects. Chronic marijuana smoke exposure 
resulted in an 'amotivational' syndrome. In utero cocaine exposure was shown to cause 
behavioral rigidity or lack of plasticity as evidenced by the difficulty of subjects to adjust to 
rules changes for some tasks. These effects were seen in adult subjects suggesting that the 
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effects of gestational cocaine exposure are long-term or permanent (see Paul, 2005 for 
review). 
3.3 Orexins in drug-seeking 
Orexins (also known as hypocretins) are recently discovered neuropeptides, synthetised 
exclusively in hypothalamic neurons, which have been shown to be important in 
narcolepsy/cataplexy and arousal (Zhou et al., 2008). Aston-Jones et al. (2009) conducted 
behavioral, anatomical and neurophysiological studies that show that a subset of these cells, 
located specifically in lateral hypothalamus (LH), are involved in reward processing and 
addictive behaviors. They found that Fos expression in LH orexin neurons varied in 
proportion to preference for cocaine or food. Recently, using a self-administration paradigm, 
it was discovered that the Ox1 orexin receptor antagonist, SB-334867 (SB), blocks cocaine-
seeking induced by discrete or contextual cues, but not by a priming injection of cocaine. 
Neurophysiological studies revealed that locally applied orexin often augmented responses 
of VTA DA neurons to activation of the mPFC, consistent with the view that orexin 
facilitates activation of VTA DA neurons by stimulus-reward associations. These findings 
are consistent with results from others showing that orexins facilitate glutamate-mediated 
responses, and are necessary for glutamate-dependent long-term potentiation, in VTA DA 
neurons (Anston-Jones et al., 2010). Boutrel et al., (2005) show that intracerebroventricular 
infusions of hypocretin-1 lead to a dose-related reinstatement of cocaine seeking without 
altering cocaine intake in rats and elevates intracranial self-stimulation threshold. The effect 
was prevented by blockade of noradrenergic and corticotrophin releasing factor systems, 
suggesting that hypocretin-1 reinstated drug seeking through induction of a stress-like state. 
3.4 Regulation of cocaine intake 
Recent studies have started to reveal the contribution of epigenetic regulation to addiction-
related behaviours and neuroadaptation. Two studies focused on the role of the X-linked 
transcriptional repressor methyl CpG-binding protein 2 (MeCP2), wich contributes to the 
development and function of CNS synapses. They showed that drugs of abuse regulate the 
expression and/or activity of MeCP2 and that this contributes to behavioural and neural 
responses to the drug. MeCP2, known for its role in the neurodevelopmental disorder Rett 
syndrome, is emerging as an important regulator of neuroplasticity in postmitotic neurons. 
Cocaine addiction is commonly viewed as a disorder of neuroplasticity (White, 1996; Everitt 
et al., 1999; Di Chiara, 1999). Heh-In et al. (2010) identified a key role for MeCP2 in the 
dorsal striatum in the escalating cocaine intake seen in rats with extended access to the drug, 
a process that resembles in some rats subjected to extended daily access to the drug, the 
increasingly uncontrolled cocaine use seen in addicted humans (See Badiani et al., 2011 for 
review). MeCP2 regulates cocaine intake through homeostatic interactions with microRNA-
212 (miR-212) to control the effects of cocaine on striatal BDNF levels. They suggest that 
homeostatic interactions between MeCP2 and miR-212 in dorsal striatum may be important 
in regulating vulnerability to cocaine addiction. Deng et al. (2010) have shown that acute 
viral manipulation of MeCP2 expression in the NAc bidirectionally modulates amphetamine 
(AMPH)-induced conditioned place preference. Mecp2 hypomorphic mutant mice have 
more NAc GABAergic synapses and show deficient AMPH-induced structural plasticity of 
NAc dendritic spines. Furthermore, these mice show deficient plasticity of striatal 
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immediate early gene inducibility after repeated AMPH administration. Notably, 
psychostimulants induce phosphorylation of MeCP2 at Ser421, a site that regulates MeCP2’s 
function as a repressor. Phosphorylation is selectively induced in GABAergic interneurons 
of the NAc, and its extent strongly predicts the degree of behavioral sensitization. These 
data reveal new roles for MeCP2, both, in mesolimbocortical circuit development, and in the 
regulation of psychostimulant-induced behaviors. Also, Im et al (2010) reported increased 
MeCP2 expression and miR-212 (as well as miR-132) levels in the dorsal striatum in rats that 
had extended access to cocaine. Knocking down striatal MeCP2 expression using small 
hairpin RNA (shRNA) promoted the cocaine-induced increase in miR-212 expression. It also 
prevented the escalation of cocaine intake that normally occurs with prolonged cocaine 
access, an effect that could be blocked by disruption of miR-212 signalling using an 
antisense oligonucleotide. Furthermore, overexpressing miR-212 in the dorsal striatum, a 
neurobiological locus of control of habitual (Belin and Everitt 2008; Belin et al., 2009, 2010, 
Zapata et al., 2010, Murray et al., 2012) and compulsive (Jonkman et al., 2012) cocaine 
seeking, using a lentiviral vector reduced MeCP2 levels and decreased cocaine intake in rats 
with extended access to the drug (Im et al., 2010). These findings indicate that miR-212 and 
MeCP2 homeostatically regulate one another in the dorsal striatum and suggest that this 
interaction has a role in controlling compulsive cocaine intake. Taken together, these results 
suggest a role for MeCP2 in the behavioural response to psychostimulant drugs, although 
many questions remain regarding the undoubtedly complex mechanisms involved in its 
interactions with microRNAs and its modulation of synaptic plasticity (Welberg, 2010).  
4. Amphetamine (Table 3) 
4.1 Dopaminergic system 
The fundamental principle that unites addictive drugs appears to be that each enhances 
synaptic DA by means that dissociate it from normal behavioral control, so that they act to 
reinforce their own acquisition. This occurs via the modulation of synaptic mechanisms that 
can be involved in learning, including enhanced excitation or disinhibition of DA neuron 
activity, blockade of DA reuptake, and altering the state of the presynaptic terminal to 
enhance evoked over basal transmission. Amphetamines offer an exception to such 
modulation in that they combine multiple effects to produce nonexocytotic, stimulation-
independent release of neurotransmitter, via reverse-transport, independent from normal 
presynaptic function (Sulzer, 2011). In addition, behavioral sensitization is accompanied by 
an increase in postsynaptic DA receptors; an increase in DA synthesis; an increase in DA 
utilization and/or release (Kalivas and Stewart, 1991; Flores et al., 2011). There is strong 
evidence to support the notion that behavioral sensitization is due to enhanced 
mesotelencephalic DA release, especially upon re-exposure to the drug (Robinson and 
Becker, 1986). The mesocorticolimbic dopamine system, which arises in the VTA and 
innervates the NAc, among numerous other regions, has been implicated in processes 
associated with drug addiction, including behavioral sensitization. The mPFC, defined as 
the cortical region that has a reciprocal innervation with the mediodorsal nucleus of the 
thalamus, is also a terminal region of the mesocorticolimbic DA system. The mPFC contains 
pyramidal glutamatergic neurons that serve as the primary output of this region and mPFC 
transmitter systems are involved in the development of behavioral sensitization to cocaine 
and amphetamine (Steketee, 2003). 
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Table 3. Plastic changes on brain regions by chronic use of amphetamine. 
(Abbreviations: AMPA: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; CaMKII: 
Ca2+/calmodulin-dependent protein kinase II CTA: conditioned taste avoidance; DA: dopamine; DAR: 
dopamine receptor eCB: endocannabinoid; LTP: long-term potentiation; LTD: long-term depression; 
mGluR: metabotropic glutamate receptor; mPFC: medial prefrontal cortex; NAc: nucleus accumbens; 
NMDA: N-Methyl-D-aspartic acid; OFC: orbital frontal cortex; PFC: prefrontal cortex; VTA: ventral 
tegmental area). 
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Intracranial self-administration (ICSA) and intracranial place conditioning (ICPC) 
methodologies have been mainly used to study drug reward mechanisms, but they have 
also been applied toward examining brain reward mechanisms (McBride et al., 1999; Di 
Chiara et al., 2004). ICSA studies in rodents have established that the VTA is a site 
supporting reinforcement. The NAc also appears to have a major role in brain reward 
mechanisms. Rodents will self-infuse a variety of drugs of abuse (amphetamine and cocaine) 
into the NAc, and this occurs primarily in the shell region. ICPC studies also indicate that 
injection of amphetamine into the shell portion of the NAc produces conditioned place 
preference (CPP). Activation of the DA system within the shell subregion of the NAc 
appears to play a key role in brain reward mechanisms. The PFC supports the ICSA of 
cocaine and phencyclidine. The DA system also seems to play a role in this behavior since 
cocaine self-infusion into the PFC can be blocked by co-infusing a D2 antagonist. Among 
other regions, ICPC findings suggest that cocaine and amphetamine are rewarding in the 
rostral ventral pallidum (VP). Finally, substance P-mediated systems within the caudal VP 
(nucleus basalis magnocellularis) and serotonin systems of the dorsal and median raphe 
nuclei may also be important anatomical components involved in brain reward 
mechanisms. Overall, the ICSA and ICPC studies indicate that there are a number discrete 
CNS sites involved in brain reward mechanisms (McBride et al., 1999). 
4.2 Amphetamine alters learning, LTP and LTD 
Recent studies suggest LTP expression in locally activated glutamate synapses onto DA 
neurons (local Glu-DA synapses) of the midbrain VTA following a single or chronic 
exposure to many drugs of abuse, whereas a single exposure to cannabinoid did not 
significantly affect synaptic plasticity at these synapses. It is unknown whether chronic 
exposure of cannabis (marijuana or cannabinoids), the most commonly used illicit drug 
worldwide, induce LTP or LTD at these synapses. Pleiotrophin (PTN) is a cytokine with 
important roles in the modulation of synaptic plasticity, which levels of expression are 
significantly regulated by amphetamine administration. Gramage et al. (2011), have 
reported that amphetamine during adolescence causes long-term cognitive deficits in rats. 
Periadolescent amphetamine treatment daily during 10 days in normal and in PTN 
genetically deficient mice result in significant deficits in the passive avoidance and Y-maze 
tests (two tasks related to learning and memory abilities), only observed in amphetamine-
pretreated PTN mutant mice. However, 13 and 26 days after the last administration, they 
did not find significant differences in Y-maze between amphetamine- and saline-pretreated 
PTN-/- mice. A significantly enhanced LTP in CA1 hippocampal slices from saline-
pretreated PTN-/- mice compared with saline-pretreated PTN+/+ mice was observed. 
Interestingly, amphetamine pre-treatment during adolescence significantly enhanced LTP in 
adult PTN+/+ mice but did not cause any effect in PTN-/- mice, suggesting LTP 
mechanisms saturation in naïve PTN-/- mice. The data demonstrate that periadolescent 
amphetamine treatment causes transient cognitive deficits and long-term alterations of 
hippocampal LTP depending on the endogenous expression of PTN. Pleiotrophin (PTN) is a 
growth factor that has been shown to be involved in hippocampal synaptic plasticity and 
learning. Del Olmo et al. (2009), using in vitro electrophysiological recordings in PTN-
stimulated CA1 from rat hippocampal slices, found that PTN inhibited hippocampal LTP 
induced by high-frequency stimulation (HFS). Also, they observed significant differences in 
recognition memory between PTN genetically deficient (PTN-/-) mice and wild type (WT) 
mice using the Y-maze test, whereas WT mice showed disruption of recognition memory, 
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PTN -/- mice maintained the recognition memory. The data demonstrate that PTN inhibits 
hippocampal LTP in vitro and might play a role in memory processes in vivo. 
Synaptic plasticity in the mesolimbic DA system is critically involved in reward-based 
conditioning and the development of drug addiction (Schultz et al., 1998; Wise, 2004). Ca2+ 
signals triggered by postsynaptic action potentials (APs) drive the induction of synaptic 
plasticity in the CNS. Ahn et al. (2010) have recently proposed that enhancement of mGluR-
dependent n-methyl-d-aspartate receptor (NMDAR) plasticity in the VTA may promote the 
learning of environmental stimuli repeatedly associated with amphetamine experience. In 
this study, using brain slices prepared from male rats, it was shown that repeated in vivo 
exposure to the psychostimulant amphetamine upregulates mGluR-dependent facilitation of 
burst-evoked Ca2+ signals in DA neurons of the VTA. Protein kinase A (PKA)-induced 
sensitization of IP3 receptors mediates this upregulation of mGluR action. As a consequence, 
NMDAR-mediated transmission becomes more susceptible to LTP induction after repeated 
amphetamine exposure. It was also found that the magnitude of amphetamine-conditioned 
place preference (CPP) in behaving rats correlates with the magnitude of mGluR-dependent 
Ca2+ signal facilitation measured in VTA slices prepared from these rats.  
Major drugs of abuse such as cocaine, amphetamine, morphine, heroine, nicotine, and ethanol 
act on glutamatergic synapses on midbrain DA neurons and lead to NMDA-dependent, 
AMPA-mediated long-term potentiation in DA neurons. Thus, excitatory influences on these 
neurons become enhanced; in particular NMDA-dependent burst firing. Amphetamine also 
leads to reduction of LTD in DA neurons (Swope et al., 1999; Ahn et al., 2010; Liu et al., 2010, 
Good and Lupica, 2010). Thus, subthreshold fluctuations of excitatory inputs to DA neurons 
would increase or even generate action potentials in the absence of reward, generating a false 
reward signal (Schultz, 2011). There are glutamatergic projections from the hippocampus to 
the NAc, which regulate DA transmission in this structure. Ventral hippocampal (VH) 
glutamatergic neurons project to the NAc shell region, whereas the dorsal hippocampus (DH) 
sends glutamatergic projections to the NAc core region. Tan (2008) investigated the roles of 
hippocampal NMDA receptors and NAc D1 receptor in AMPH-produced conditioned place 
preference (AMPH-CPP) in rats. It was shown that AMPH-CPP results in the enhancement of 
hippocampal CaMKII activity which can be impaired by NMDA antagonist (AP5). 
Inactivation of hippocampal area (dorsal hippocampus or ventral hippocampus) impaired 
AMPH-CPP, but its effect was diminished by the activation of D1 receptors in NAc core or 
NAc shell. It was concluded that if the deterioration of AMPH-CPP expression resembles the 
formation of new learning, then this active process might have been facilitated by the 
hippocampal NMDA receptor activations during testing. 
4.3 Amphetamine sensitization 
Muhammad et al. (2011a) studied the effect of postnatal tactile stimulation (TS) on juvenile 
behavior, adult amphetamine (AMPH) sensitization, and the interaction of TS and AMPH on 
prefrontal cortical (PFC) thickness and striatum size. AMPH administration resulted in 
gradual increase in behavioral sensitization that persisted at least for 2 weeks. However, TS 
rats exhibited attenuated AMPH sensitization compared to sex-matched controls. 
Neuroanatomically, AMPH reduced the PFC thickness in control females but enlarged the 
posterior striatum in control males. It was suggested that TS during development modulated 
the response to novel objects and altered social behaviors and attenuated AMPH-induced 
behavioral sensitization by preventing drug-induced structural alteration in the PFC and the 
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striatum, brain regions implicated in drug abuse. Subsequently, these same investigators 
studied the effect of prenatal stress (PS) on juvenile behavior and adult AMPH sensitization, as 
well as the effect of the interaction between experience and drug on cortical thickness and 
neuronal morphology in corticolimbic regions in rats. PS did not influence AMPH-induced 
behavioral sensitization in either male or female rats. Moreover, PS increased the spine density 
in the NAc and decreased it in the mPFC without any alteration in the orbital frontal cortex 
(OFC). Similarly, AMPH administration increased spine density in the NAc and mPFC, 
whereas a decrease was observed in the OFC. However, PS prevented the drug-induced 
alterations in the spine density observed in controls. In sum, PS modulated juvenile behavior 
and altered brain morphology without influencing AMPH-induced behavioral sensitization 
substantially (Muhammad and Kolb, 2011b). Also, more recently Muhammad and Kolb 
(2011c) studied the long-term influence of maternal separation (MS) on periadolescent 
behavior, adult amphetamine (AMPH) sensitization, and structural plasticity in the 
corticolimbic regions in rats. Male and female pups, separated daily for 3h from the dam 
during postnatal day 3-21, were tested for periadolescent exploratory, emotional, cognitive, 
and social behaviors. The results showed that MS enhanced anxiety-like behavior in males. 
Repeated AMPH administration increased the spine density in the NAc and the mPFC, and 
decreased it in the OFC. MS blocked the drug-induced alteration in these regions. MS during 
development influenced periadolescent behavior in males, and structurally reorganized 
cortical and subcortical brain regions without affecting AMPH-induced behavioral 
sensitization. 
4.4 Amphetamine and mental disorders 
Individuals who repeatedly use stimulant drugs, such as AMPH, develop an AMPH-
induced psychosis that is similar to paranoid schizophrenia. There has been, therefore, 
considerable interest in characterizing the effects of chronic stimulant drug treatment on 
brain and behavior in non-human animals (Robinson and Becker, 1986). 
5. Dopamine transporter and neural plasticity 
Dopamine (DA) is one of the most important neurotransmitters affecting fine brain processes. 
Dysfunction of dopaminergic neurotransmission precipitates diseases such as Parkinson’s 
disease (PD), schizophrenia, attention-deficit hyperactivity disorder (ADHD), and drug 
addiction (see Zhang et al., 2010 for review). DA synthesis occurs within the DA neurons. 
Tyrosine is transported into the cell via amino acid carriers in the blood–brain barrier and cell 
membranes. Once in the intracellular space, tyrosine is hydroxylated to L-3,4-
dihydroxyphenylalanine (L-DOPA) by tyrosine hydroxylase (TH). L-DOPA is then 
decarboxylated by aromatic acid decarboxylase (AADC) to DA (for review see Miyake et al., 
2011). Extracellular DA concentration and lifetime after release is regulated by diffusion, 
dilution as well as reuptake (for review see Rice and Cragge, 2008). Reuptake of synaptic DA 
by the dopamine transporter (DAT) is the principal mechanism regulating dopamine 
neurotransmission, and is often used as a marker for presynaptic DA function (for review see 
Zhang et al., 2010). In addition DA itself can regulate DAT via its interaction with the 
transporter or presynaptic autoreceptors (Williams and Galli, 2006). Interestingly, a recent 
report has found that unmedicated bipolar disorder (BPD) subjects had significantly lower 
DAT availability relative to healthy controls in bilateral dorsal caudate (Anand et al., 2011), 
thus the authors suggest that DAT availability may be related to the neuropathology of BPD. 
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The DAT is a target for the development of pharmacotherapies for a number of central 
disorders including PD, Alzheimer's disease, schizophrenia, Tourette's syndrome, Lesch-
Nyhan disease, ADHD, obesity, depression, and stimulant abuse, as well as normal aging 
(for review see Runyon and Carroll, 2006). DAT is located on the presynaptic membrane of 
DA terminals and regulates phasic DA transmission at the synapse by rapidly removing DA 
from the synaptic cleft through reuptake (for review see Rice and Cragge, 2008). 
Interestingly, this protein is expressed exclusively by DA neurons and is found 
extrasynaptically on DA axons in CPu and NAc (for review see Rice and Cragge, 2008). In 
addition, DA receptors are also predominantly extrasynaptic (Sesack et al., 1994; Yung et al., 
1995; Hersch et al., 1995; Khan et al., 1998). Interestingly, several recent reports suggest that 
synuclein proteins have a critical role in monoamine neurotransmitter homeostasis. In 
addition, the physical interactions between synuclein proteins and monoamine transporters 
(DA, serotonin (5HT) and norepinephrine (NE) transporters) indicate an important role for 
the synucleins in regulating transporter function, trafficking and distribution at the DA, 5HT 
and NE synapses (for review see Oaks and Sidhu, 2011).  
The synuclein family of proteins includes α-synuclein (α-Syn), β-synuclein (β-Syn), and γ-
synuclein (γ-Syn). The genes cloned from multiple species demonstrate that synucleins, a 
group of prevalent pre-synaptic proteins, are highly conserved, but unique to vertebrate 
organisms (Surguchov, 2008). In addition, these proteins participate in numerous 
interactions with other proteins, lipid membranes, and nucleic acids, suggesting a possible 
role in the chaperoning or trafficking of biomolecules (Surguchov, 2008). Two-hybrid and 
immunoprecipitation experiments have identified a physical interaction between α-Syn and 
the carboxy terminal of DAT (Lee et al., 2001). In addition, release of DA synthesized by DA 
neurons in the brain requires packaging of the neurotransmitter into vesicles by the 
vesicular monoamine transporter 2 (VMAT2). VMAT2 co-localizes with α-Syn in the Lewy 
bodies of PD (Yamamoto, 2006), and overexpression of α-Syn can disrupt VMAT2 function 
(Surguchov, 2008). However, the influence of β-Syn and γ-Syn upon VMAT2 expression and 
activity are not known. Recent reports suggest that psychostimulants such as amphetamines 
and cocaine induced overexpression of α-synuclein (Fornai et al., 2005; Mauceli et al., 2006; 
Ajjimaporn et al., 2007; Klongpanichapak et al., 2008; Mukda et al., 2011, Sae-Ung et al., 
2011). Interestingly, recent reports suggest that low levels of the γ-synuclein in the NAc 
results to an increased self-administration of cocaine in the rat (Boyer et al., 2011). In 
addition, cocaine induced a 1.9-fold increase in locomotor activity after overexpression of α-
synuclein in the NAc (Boyer and Dreyer, 2007). It is noteworthy that the neurotoxicity 
induced by the psychostimulants such as amphetamine are mediated by enhanced oxidative 
stress and these effects are abolished by melatonin (Govitrapong et al., 2010), a main 
secretory product of pineal gland. Interestingly, a recent report suggested that this 
melatonin effect is mediated by the reduction of the overexpression of α-synuclein induced 
by amphetamine (Sae-Ung et al., 2011). 
Amphetamines and cocaine are psychostimulants with a target in the monoaminergic 
system. These drugs reverse the action of monoamine transporters and enhance the release 
of DA as well as norepinephrine and 5-hydroxytriptamine (5-HT, serotonin) into the 
synaptic cleft, increasing their availability to act upon post-synaptic receptors. Reuptake 
blocking and decreased degradation of these neurotransmitters increases their 
concentrations in the synaptic cleft.  
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Locomotor activity induced by psychostimulants such as amphetamine is the result  
of increases in synaptic DA, by blocking or reversing the direction of DAT (Sulzer et al., 
1995; Sulzer et al., 2005), which in turn acts on postsynaptic receptors. Interestingly, mice 
lacking DAT exhibit spontaneous hyperlocomotion and are unresponsive to amphetamine 
(Giros et al., 1996). Recent reports suggest that DAT, but not the serotonin transport (SERT), 
is critical in mediating the reinforcing effects of cocaine. In addition, mice lacking DAT 
generally failed to acquire and maintain cocaine self-administration (Thompson et al., 2009) 
compared to wild-type or SERT-/- mice. Therefore, DAT may play a role in mediating the 
long-lasting neural changes associated with drug addiction (Martin et al., 2011; Schmitt and 
Reith 2010). 
Drug addiction involves several molecules such as CART (Cocaine-and amphetamine-
regulated transcript) peptide. This peptide is a neurotransmitter believed to play a 
homeostatic role in psychostimulant reward and reinforcement, as well as in other processes 
(Jaworski and Jones, 2006; Rogge et al., 2008). CART has also been proved to attenuate 
locomotion induced by direct intraaccumbal injections of DA (Jaworski et al., 2003). 
Recently, it has been documented that the role of CART peptide in the NAc is to 
homeostatically regulate the activity of the DA system (Rogge et al., 2008). Moreover CART 
mRNA and CART peptide are found abundantly in the NAc (Douglass et al., 1995; Koylu et 
al., 1998). CART peptide (CART55-1029) has been shown to have minor psychostimulant-
like properties when injected into the VTA, inducing locomotor activity and producing a 
slightly conditioned place preference (Kimmel et al., 2000, 2002). In this sense, a new study 
supports the idea that CART peptide reduces the effects of psychostimulants by modulating 
the simultaneous activation of both D1 and D2 receptors, rather than by affecting the action 
of any individual DA receptor (Moffett et al., 2011). In addition, our recent report suggests 
that prenatal amphetamine exposure produced, at postpubertal age, an enhanced DAT in 
the NAc (Flores et al., 2011, Figures 2, 3, 4) and children with prenatal psychostimulant 





























































































































Fig. 2. Effect of amphetamine on locomotor behavior in a novel environment. A) Analysis of 
total activity scores revealed that the rats at PD60 were more active after amphetamine 
injection than their corresponding control group. B) Temporal profile of locomotor activity 
at PD60. C) Rats with prenatal amphetamine exposure were less active than control animals. 
Modified from Flores et al., 2011. 
 



















Fig. 3. Quantitative autoradiographic analysis of [3H]- SCH-23390/dopamine D1-like 
receptor binding, [3H]-spiperone/dopamine D2-like receptor binding, [3H]7-
OHDPAT/dopamine D3 receptor binding and [3H] WIN-35428/dopamine transporter 
binding in prenatal amphetamine exposure (PAE)- and prenatal vehicle exposure (PVE)-rats 
Dopamine (DA), Postnatal (PD), nucleus accumbens (NAcc), caudate–putamen (CPu), 
olfactory tubercle (OT) and the island of Calleja. (Modified from Flores et al., 2011).  
 




















Fig. 4. Photomicrograph showing representative Golgi-Cox-impregnated medium spiny 
neurons and spines dendritic from the nucleus accumbens. Neurons in the nucleus 
accumbens core (A) and shell (B). The spine density is higher at PD60 in the dendritic 
segments from the core (A2) and shell (B2) subregions of the NAc of rats prenatally exposed 
to amphetamine compared to their corresponding vehicle group. 
Cocaine and amphetamine may induce neural changes, including an increase in the density 
of spines on neuron dendrites in the NAc and PFC (Robinson and Kolb, 2004) associated 
with locomotor sensitization (Manev and Uz, 2009). More recently it has been suggested that 
cocaine-induced dendritic spine changes are correlated with the presence of DAT, because 
mice lacking DAT did not show an increase in dendritic spine density in the NAc (Martin et 
al., 211). In addition, the stereotypy induced by cocaine is also absent in this transgenic mice 
(Tilley and Gu, 2008). However, amphetamine and cocaine, although similar in many 
respects, do not produce identical patterns of structural plasticity when given to rats at 
different ages. In adult rats, several reports have demonstrated that cocaine increases spine 
density on the basilar dendrites of pyramidal neurons in the PFC, while amphetamine has 
either no effect or a weak effect on these dendrites. In contrast, in juvenile (P22–P34) rats, 
amphetamine increases spine density on the basilar dendrites of PFC (for review see 
Robinson and Kolb, 2011).  
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In conclusion, DAT is one of the principal mechanisms regulating DA neurotransmission via 
reuptake of synaptic DA. The psychostimulants amphetamine and cocaine alter DAT 
function and alter the lifetime of the DA after release. Exposure to amphetamine or cocaine 
produced persistent changes in the structure of dendrites and dendritic spines in brain 
regions such as the NAc and PFC, limbic structures related with the addictions. This 
structural plasticity associated with the use of the drugs of abuse results in a reorganization 
of synaptic connectivity in these neural systems, which may associate with addiction 
symptoms. Several reports suggest that cocaine abusers have an increase in DAT levels with 
a decrease in gray and white matter density (Gould et al., 2011), however, abstainers have 
significantly higher gray matter density and lower DAT levels than current cocaine users 
(Hanlon et al., 2011; Gould et al., 2011). Therefore, both, DAT levels and gray matter density 
in cocaine users reverse after prolonged abstinence (Volkow et al., 2001; Beverigde et al., 
2009; Hanlon et al., 2011). Interestingly, cocaine abstainers perform better cognitive test 
compared to current cocaine users (Hanlon et al., 2011). 
6. Treatment of addiction 
Despite intensive research and significant advances, drug addictions remain a substantial 
public health problem. Drug addictions have a high economical cost annually and impact 
not only the addicted individuals, but also their spouses, children, employers, and others. 
Thus, the development of improved prevention and treatment strategies is of importance 
(Potenza et al., 2011). Learning processes have been shown to play a major role in the 
maintenance of addictive behaviour (Everitt et al., 1999; Robbins & Everitt, 2002; Everitt & 
Robbins, 2005; Moreira & Lutz, 2008; Liu et al., 2010). Humans and animals rapidly learn 
cues and contexts that predict the availability of addictive drugs. Once learned, these cues 
and contexts initiate drug seeking, craving and relapse in both animal models and clinical 
studies (Von der Goltz & Kiefer, 2009; De Vries & Schoffelmeer, 2005; Micale et al., 2007). 
Evidence suggests that several types of neuroadaptation occur, including synapse-specific 
adaptations of the type thought to underlie specific long-term associative memory. Thus, 
understanding learning and memory processes in the addicted is an important key for 
understanding the persistence of addiction, and it is reasonable to hypothesize that the 
disruption of drug-related memories may help to prevent relapses (von der Goltz & Kiefer, 
2009). The study of structure-activity relationships of molecules which influence the 
cannabinoid system in the brain and body is crucial in the search of medical preparations 
with the therapeutic effects of the phytocannabinoids without the negative effects on 
cognitive function attributed to cannabis (see Fisar, 2009 for review).  
As discussed before, cannabinoid CB1Rs are novel targets for a new class of therapeutic 
agents used to treat drug addiction. Blockade of the CB1 receptor is particularly effective in 
reducing cue-induced reinstatement of drug seeking, an animal analogue of cue-induced 
relapse in human addicts (See Gardner, 2002, 2005, 2011 for review). These relapse-
preventing properties are observed with different classes of abused drug (i.e. 
psychostimulants, opiates, nicotine and alcohol). In addition, recent evidence indicates a 
more general role of CB1 receptors in reward-related memories, which is consistent with the 
proposed role of endocannabinoids in memory-related plasticity. Relapse-preventing 
actions and inhibitory effects on weight gain were confirmed recently in clinical trials with 
the CB1 antagonist rimonabant (De Vries and Schoffelmeer, 2005). Preclinical results 
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provide support for the suggestion that targeting the endocannabinoid system may aid in 
the treatment of disorders associated with impaired extinction-like processes, such as post-
traumatic stress disorder (Abush and Akirav, 2010). Liu et al. (2010) provided evidence that 
NMDA receptor-dependent synaptic depression at VTA dopamine circuitry requires GluR2 
endocytosis, also suggest an essential contribution of such synaptic depression to 
cannabinoid-associated addictive learning, in addition to pointing to novel pharmacological 
strategies for the treatment of cannabis addiction. They found in rats that chronic 
cannabinoid exposure activates VTA CB1 receptors to induce transient neurotransmission 
depression at VTA local Glu-DA synapses through activation of NMDA receptors and 
subsequent endocytosis of AMPA receptor GluR2 subunits. A GluR2-derived peptide blocks 
cannabinoid-induced VTA synaptic depression and conditioned place preference, i.e., 
learning to associate drug exposure with environmental cues.  
6.1 Pharmacological treatments and targets 
Multiple pharmacological targets have been identified for the treatment of addictive 
disorders. ‘‘Classic’’ approaches tend to target the drug ‘‘reward’’ system, such as 
normalization of function through agonist approaches and negative reinforcement 
strategies. Agonist medications have their main impact on the same types of 
neurotransmitter receptors as those stimulated by abused substances. Most notably, 
dextroamphetamine has reduced drug use in short-term clinical trials in cocaine and 
methamphetamine users. The long-term safety and abuse liability of amphetamines as a 
treatment for cocaine addiction remains to be determined. Another example of an agonist 
approach for cocaine dependence is modafinil, a weak DAT inhibitor and increases synaptic 
DA levels, which has stimulant-like effects. On other hand, antagonists block the effects of 
drugs by either pharmacological or pharmacokinetic mechanisms. More recently, 
immunotherapies have been developed for the treatment of cocaine and methamphetamine 
addictions. The antibodies produced by immunotherapies sequester the drug in the 
circulation and reduce the amount of drug and the speed at which it reaches the brain. A 
potentially promising target for agonist and antagonist treatment of cocaine addiction is the 
D3 dopamine receptor. D3 partial agonists can act like agonists and stimulate DA receptors 
when endogenous levels of dopamine are low, as in cocaine withdrawal. An important 
limitation of vaccines is that the antibodies produced are specific for a given drug of abuse, a 
characteristic that will limit their clinical efficacy in polydrug abusers.  
Drug addiction is associated with adaptive changes in multiple neurotransmitter systems in 
the brain. These adaptive changes are thought to underlie the negative reinforcing effects of 
abstinence from drug use that are clinically observed as withdrawal symptoms, craving for 
drug use, and negative mood states like anhedonia and anxiety (Hasin et al., 2007; Treadway 
and Zald, 2011). Examples of medications targeting negative reinforcement of drugs include 
methadone or buprenorphine, drugs that relieve opioid withdrawal symptoms. Cocaine users 
with more severe withdrawal symptoms respond more favorably to propranolol, a beta-
adrenergic antagonist (Kampman et al., 2006). Several agents targeting glutamate system are 
also under investigation as potential treatment medications. Memantine, a noncompetitive 
NMDA glutamate receptor antagonist, may be efficacious and operate by reducing cognitive 
measures of compulsivity (Grant et al., 2010). However, clinical trials with an NMDA receptor 
antagonist have demonstrated negative findings for cocaine dependence (Bisaga et al., 2010). 
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Activation of cannabinoid receptors on synaptic terminals results in regulation of ion channels, 
neurotransmitter release and synaptic plasticity. Neuromodulation of synapses by the 
cannabinoids is proving to have a wide range of functional effects, making them potential 
targets as medical preparations in a variety of illnesses, including some mental disorders and 
neurodegenerative illnesses (see Fisar, 2009 for review).  
In conclusion, the review of existing evidences indicates that addictive drugs induce 
synaptic plasticity at DA system and produce changes in DA at different target structures of 
the brain, affecting glutamateric, GABAergic transmission and LTP and LTD processes 
(Figure 5). New research will without doubt shed light onto the mechanisms of addiction 






















Fig. 5. Addictive drug affects DA levels, glutamatergic and GABAergic transmission and 
LTP and LTD processes at different brain structures. DA: dopamine; CA1: CA1 region of the 
hippocampus; PFC, prefrontal cortex; NAc: accumbens nucleus; BLA: basolateral amygdala.  
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